XM does not provide services to residents of the United States of America.
T
T

Tenaris

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Draegerwerk, Hikma, Novartis

EUROPE RESEARCH ROUNDUP-Draegerwerk, Hikma, Novartis Sept 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Draegerwerk, Hikma and Novartis, on Tuesday. HIGHLIGHTS * Draegerwerk DRWG.DE : Jefferies raises to hold from underperform * Hikma HIK.L : Berenberg raises to buy from hold * Munters Group AB MTRS.ST : Jefferies raises to buy from hold * Novartis AG NOVN.S : Jefferies cuts to hold from buy * Swedencare AB (Publ) SECARE.ST : J
A
A
A
B
B
B
C
D
G
H
H
N
S
T
U
A
P

Senators want Biden to lower South Korean import quota for piping products

UPDATE 2-Senators want Biden to lower South Korean import quota for piping products Adds Commerce Department, company, industry reaction in paragraphs 3-4 and 7 By David Shepardson WASHINGTON, Aug 30 (Reuters) - Three Democratic U.S. senators urged the Biden administration on Friday to reduce the import quota on oil and gas drilling pipes from South Korea, saying it has affected companies with operations in Ohio and Pennsylvania.
T

Senators want Biden to lower South Korean import quota for piping products

Senators want Biden to lower South Korean import quota for piping products WASHINGTON, Aug 30 (Reuters) - Three Democratic U.S. senators on Friday urged the Biden administration to reduce the current import quota set on oil and gas drilling pipes from South Korea, saying it has impacted companies with operations in Ohio and Pennsylvania. The senators -- Sherrod Brown of Ohio and Bob Casey and John Fetterman of Pennsylvania noted the market for products known as Oil Country Tubular Goods, used fo
T

U.S. Aadi Bioscience, Target, Visteon

U.S. RESEARCH ROUNDUP-Aadi Bioscience, Target, Visteon Aug 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aadi Bioscience, Target and Visteon, on Thursday. HIGHLIGHTS * Aadi Bioscience Inc AADI.O : Jefferies cuts to hold from buy * Assurant Inc AIZ.N : Piper Sandler cuts to neutral from overweight * Estée Lauder EL.N : Piper Sandler raises to overweight from neutral * Target Corp TGT.N : Jefferies raises target
A
A
H
S
T
T
U
A
P
U
D
E
A

Tenaris Completes $1.2 Bln Buyback

BRIEF-Tenaris Completes $1.2 Bln Buyback Aug 5 (Reuters) - Tenaris SA TENR.MI : SAID ON FRIDAY IT HAD COMPLETED BUYBACK PROGRAMME FOR $1.2 BLN TOTAL CONSIDERATION Further company coverage: TENR.MI (Gdansk Newsroom)
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.